Modifications of human carboxylesterase for improved prodrug activation

Abstract

Background: Carboxylesterases (CEs) are ubiquitous enzymes responsible for the hydrolysis of numerous clinically useful drugs. As ester moieties are frequently included in molecules to improve their water solubility and bioavailability, de facto they become substrates for CEs. Objective: In this review, we describe the properties of human CEs with regard to their ability to activate anticancer prodrugs and demonstrate how structure-based design can be used to modulate substrate specificity and to increase efficiency of hydrolysis. Methods: A specific example using CPT-11 and a human liver CE is discussed. However, these techniques can be applied to other enzymes and their associated prodrugs. Results: Structure-guided mutagenesis of CEs can be employed to alter substrate specificity and generate novel enzymes that are efficacious at anticancer prodrug activation.

Keywords::

• carboxylesterase
• CPT-11
• enzyme/prodrug therapy
• mutagenesis
• rationale enzyme design

Acknowledgments

The Potter lab is supported by grants from the NIH (CA76202, CA79763, CA98468, CA108775, CA113446, DA018116, Cancer Center Core grant CA21765) and by the American Lebanese Syrian Associated Charities.